Market Overview

UPDATE: Credit Suisse Downgrades InterMune as Balanced Risk/Reward is Reflected in Price

Related ITMN
What You Need to Know About the Roche-InterMune Deal
Markets Reverse Early Morning Losses; Still Lower On The Day

In a report published Friday, Credit Suisse analyst Ravi Mehrotra downgraded the rating on InterMune (NASDAQ: ITMN) from Outperform to Neutral, but reiterated the $33.00 price target.

In the report, Credit Suisse noted, “Our $33 TP, Esbriet estimates, and P&L modeling remain unchanged (after our inclusion of US Esbriet revenues following positive ASCEND data earlier this week). With the stock price around our target price and the balance of risk/reward reflected in the stock price, we move ITMN to Neutral based on the key points/observations below.”

InterMune closed on Thursday at $30.65.

Latest Ratings for ITMN

Aug 2014UBSDowngradesBuyNeutral
Aug 2014Cowen & Co.Initiates Coverage onMarket Perform
Aug 2014JMP SecuritiesDowngradesMarket OutperformMarket Perform

View More Analyst Ratings for ITMN
View the Latest Analyst Ratings

Posted-In: Credit Suisse Ravi MehrotraAnalyst Color Downgrades Analyst Ratings


Related Articles (ITMN)

View Comments and Join the Discussion!